A Novel, Regulated Gene Therapy (NGN-401) Study for Female Children with Rett Syndrome

Recruiting

Phase 1

Phase 2

A Novel, Regulated Gene Therapy (NGN-401) Study for Female Children with Rett Syndrome

Sponsor:

Neurogene Inc.

Code:

NCT05898620

Conditions

Rett Syndrome

Eligibility Criteria

Sex: Female

Age: 4 - 10

Healthy Volunteers: Not accepted

Interventions

NGN-401

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information